ElsaLys Biotech at a glance
ELSALYS BIOTECH is a clinical stage immuno-oncology company which designs and develops a new generation of therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment.
To convert these novel targets into drug candidates, the Company is currently conducting 3 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.
Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster LYON BIOPOLE. As announced in May 2020, the company is a wholly owned subsidiary of Mediolanum Farmaceutici Spa.